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Human periodontal ligament (hPDL) ﬁbroblasts play a major role during periodontitis and orthodontic tooth movement,
mediating periodontal inﬂammation, osteoclastogenesis, and collagen synthesis. The highly COX-2-selective NSAID etoricoxib
has a favorable systemic side eﬀect proﬁle and high analgesic eﬃcacy, particularly for orthodontic pain. In this in vitro study, we
investigated possible side eﬀects of two clinically relevant etoricoxib concentrations on the expression pattern of mechanically
strained hPDL ﬁbroblasts and associated osteoclastogenesis in a model of simulated orthodontic compressive strain occurring
during orthodontic tooth movement. hPDL ﬁbroblasts were incubated for 72 h under physiological conditions with etoricoxib at
0 μM, 3.29 μM, and 5.49μM, corresponding to clinically normal and subtoxic dosages, with and without mechanical strain by
compression (2 g/cm2) for the ﬁnal 48 h, simulating conditions during orthodontic tooth movement in compressive areas of the
periodontal ligament. We then determined gene and/or protein expression of COX-2, IL-6, PG-E2, RANK-L, OPG, ALPL,
VEGF-A, P4HA1, COL1A2, and FN1 via RT-qPCR, ELISA, and Western blot analyses as well as apoptosis, necrosis, cell
viability, and cytotoxicity via FACS, MTT, and LDH assays. In addition, hPDL ﬁbroblast-mediated osteoclastogenesis was
assessed by TRAP staining in coculture with RAW267.4 cells for another 72 h. Gene and protein expression of all evaluated
factors was signiﬁcantly induced by the mechanical compressive strain applied. Etoricoxib at 3.29 μM and 5.49μM signiﬁcantly
inhibited PG-E2 synthesis, but not COX-2 and IL-6 gene expression nor RANK-L-/OPG-mediated osteoclastogenesis or
angiogenesis (VEGF-A). Extracellular matrix remodeling (COL1A2, FN1) and bone anabolism (ALPL), by contrast, were
signiﬁcantly stimulated particularly at 5.49μM. In general, no adverse etoricoxib eﬀects on hPDL ﬁbroblasts regarding
apoptosis, necrosis, cell viability, or cytotoxicity were detected. Clinically dosed etoricoxib, that is, a highly selective COX-2
inhibition, did not have substantial eﬀects on hPDL ﬁbroblast-mediated periodontal inﬂammation, extracellular matrix
remodeling, RANK-L/OPG expression, and osteoclastogenesis during simulated orthodontic compressive strain.
1. Introduction
The human periodontal ligament (hPDL) ﬁbroblast is the
major cell type occurring within the periodontal ligament,
a ﬁber- and cell-rich connective tissue, which adjoins teeth
to the surrounding alveolar bone of the jaws [1, 2]. The
resulting dentoalveolar joint of limited mobility (gomphosis)
enables a physiological transformation of otherwise bone-
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catabolic masticatory compressive forces into tensile ana-
bolic forces via speciﬁcally aligned collagen ﬁbers connecting
the tooth cementum to the cortical inner bony surface of the
tooth socket [2, 3]. Due to its high perfusion rate, the peri-
odontal ligament also sustains the surrounding tissue and
numerous embedded nerve endings and receptors are involved
in proprioception and the regulation of mastication [2].
hPDL ﬁbroblasts have been shown to play an important
role not only in homeostasis and turnover of the periodontal
ligament [4] but also in the mediation and regulation of
various physiological and pathological processes [1, 5, 6]. In
particular, they are known to react to bacterial toxins and
lipopolysaccharides of periodontal pathogens, which are
recognized by Toll-like receptors, with increased expression
and release of inﬂammatory cytokines, chemokines, and
other factors leading to increased osteoclastogenesis via the also
upregulated RANK-L/OPG system [7] and causing uncon-
trolled loss of periodontal attachment and bone (periodontitis)
[8, 9]. Apart from toxins, also mechanical stimuli by compres-
sive or tensile forces have been shown to trigger similar
reactions [6, 10], possibly mediated by integrin-associated
mechanotransduction via focal adhesions [11].
In the dental discipline of orthodontics, these hPDL
ﬁbroblast-mediated pseudoinﬂammatory, multicellular,
immunological processes are necessary to enable controlled
osteoclastogenesis to move teeth through the alveolar bone
[6, 11]. Orthodontic tooth movement is induced therapeuti-
cally by applying mechanical forces to the teeth to correct
pathologies in tooth position [6, 12], being a contributing fac-
tor for various oral diseases such as caries [13] and periodon-
titis [14]. In addition, remodeling processes of the extracellular
matrix as well as increased angiogenesis, osteoblastogenesis,
and bone formation, mediated by hPDL ﬁbroblasts [1, 4, 6],
play an integral part in orthodontic tooth movement [11].
Various pharmacologically active substances have been
shown to inﬂuence the expression pattern of hPDL ﬁbro-
blasts and hPDL ﬁbroblast-mediated osteoclastogenesis dur-
ing pathological periodontal inﬂammation (periodontitis)
[15] as well as physiological orthodontic tooth movement
[10, 16–18], that is, mechanical compressive and tensile
strain. Drugs can thus have a signiﬁcant attenuating or prop-
agating eﬀect on the regulation of these processes, which can
be either desirable or detrimental for treatment purposes
[19]. Nonsteroidal anti-inﬂammatory drugs (NSAID) are
among the most frequently used analgesics worldwide, often
available without prescription over the counter and used for
the treatment of pain, fever, and inﬂammation in general as
well as chronic inﬂammatory diseases such as rheumatoid
arthritis [19, 20]. In orthodontics, these are also used to treat
orthodontically induced pain sensations, which can other-
wise prompt termination or rejection of treatment [21].
Furthermore, due to an increasing number of adult patients
opting for orthodontic treatment [22], regular systemic
medication with NSAID for other medical conditions is
encountered more and more frequently in orthodontic
practice [19].
Etoricoxib, which has been approved in Europe for clinical
use in the treatment of various inﬂammatory diseases as well
as postoperative dental pain, belongs to a special subgroup of
NSAID called coxibs, which particularly target the
inﬂammation-induced cyclooxygenase isoform 2 (COX-2)
over the constitutively expressed isoform 1 (COX-1) to various
degrees [23] with etoricoxib being the most COX-2-selective
coxib currently available (COX-2/1 ratio of 344 : 1) one [24,
25]. Apart from being the only coxib approved for use in den-
tal context, it has been shown to have superior analgesic eﬃ-
cacy with a favorable side eﬀect proﬁle compared to other
NSAID [26, 27], particularly regarding orthodontic pain [28,
29]. For this reason, it has been identiﬁed as potential analgesic
of choice in orthodontics [29]. Since prostaglandin release by
hPDL ﬁbroblasts has been shown to play an important role
during the pseudoinﬂammatory molecular processes enabling
orthodontic tooth movement [30–32], an etoricoxib-induced
inhibition of prostaglandin synthesis might, however, have
deleterious eﬀects on hPDL ﬁbroblast-mediated osteoclasto-
genesis and thus tooth movement, possibly limiting its suit-
ability as analgesic in orthodontics.
At present, no studies are available investigating the
eﬀects of etoricoxib on hPDL ﬁbroblast-mediated periodon-
tal inﬂammation, osteoclastogenesis, angiogenesis, and
turnover of the extracellular matrix and bone formation
occurring during orthodontic tooth movement induced by
mechanical strain on hPDL ﬁbroblasts. Previous in vitro
and animal studies on other NSAIDs indicate suppressive
eﬀects [33] with available data; however, they are conﬂicting
[15, 19, 20, 23]. This is most likely due to dose dependencies
of pharmacodynamic eﬀects or a possibly diﬀerent relative
signiﬁcance of COX-2 and COX-1 in the mediation of the
pseudoinﬂammatory processes in the orthodontic context,
which merits further investigation.
The aim of this study was therefore to elucidate the
eﬀects of etoricoxib on the hPDL ﬁbroblast expression
pattern and hPDL ﬁbroblast-mediated osteoclastogenesis
in the presence and absence of physiological mechanical
compressive strain, occurring during orthodontic tooth
movement, at cell medium concentrations corresponding
to clinically administered dosages and associated local
tissue concentrations.
2. Material and Methods
2.1. hPDL Fibroblast Cultivation and Origin. Pooled primary
human periodontal ligament (hPDL) ﬁbroblast cell lines
from six patients (3 females, 3 males; age: 17-27 years) were
extracted from periodontal connective tissue of human
caries-free wisdom teeth, which were surgically removed
for medical reasons in our facility. The cultivation and
experimental usage of these human cells were approved by
the ethics committee of the University of Regensburg,
Germany (approval number 12-170-0150). To establish
hPDL ﬁbroblast cell lines, we scraped connective tissue resi-
dues oﬀ the middle third of the roots and transferred them
to 6-well plates, cultivated under standard cell culture condi-
tions (37°C, 5% CO2, and 100% H2O) in full medium
(DMEM high glucose, D5796, Sigma-Aldrich, Munich,
Germany), supplemented with 10% FCS (P30-3306, PAN-
Biotech, Aidenbach, Germany), 1% L-glutamine (SH30034.01,
GE Healthcare Europe, Munich, Germany), 100μM ascorbic
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acid (A8960, Sigma-Aldrich), and 1% antibiotics/antimy-
cotics (A5955, Sigma-Aldrich). We conﬁrmed the hPDL
ﬁbroblast lineage according to the expression of PDL-
speciﬁc marker genes (PCR ampliﬁcation and agarose gel
electrophoresis) and spindle-shaped morphology [34]
(Supplementary Figure/Table 1). Until use, all hPDL
ﬁbroblasts were stored in liquid nitrogen (90% FCS, 10%
DMSO, and freezing at 1°C/minute).
2.2. Experimental Design. At a density of 70000 cells in 2ml
DMEM per well, pooled hPDL ﬁbroblasts (3-5th passage)
were seeded onto 6-well cell culture plates. For RT-qPCR anal-
yses as well as LDH/MTT assays, hPDL ﬁbroblasts in six
experimental groups with 9 wells (n = 9) on three plates
(N = 3) each were, respectively, incubated with either 0μM
(control), 3.29μM, or 5.49μMetoricoxib (Etoricoxib VETRA-
NAL™ analytical standard: 32097 FLUKA, Sigma-Aldrich®,
Taufkirchen, Germany) for 72h, corresponding to assumed
local concentrations reached in the PDL during normal and
subtoxic clinical dosing in man [35, 36], with or without (3/3
wells per plate) compressive mechanical strain of 2 g/cm2 for
48h after a 24h preincubation phase by means of a glass disc
according to a published and well-established protocol for the
simulation of compressive orthodontic mechanical strain [30,
34] (Figure 1(a)). RANK-L Western blot was performed for
seven (N = 7), ELISA for six (N = 2, n = 6), and FACS analyses
in duplicates for three (N = 3, n = 6) biological replicates
(Figure 1(b)).
2.3. Real-Time Polymerase Chain Reaction (RT-qPCR) for
Relative Gene Expression Quantiﬁcation. RNA isolation and
quality assessment as well as RT-qPCR were performed as
described before according to MIQE guidelines [34]. Total
RNA was retrieved from hPDL ﬁbroblasts by administering
1ml peqGOLD TriFast™ (PEQLAB Biotechnology GmbH,
Erlangen, Germany) per well and further handling accord-
ing to the manufacturer’s instructions. The obtained RNA
pellet was eluted in 25μl nuclease-free water (T143, BioSci-
ence Grade, Carl Roth GmbH & Co. KG, Karlsruhe, Ger-
many) and immediately cooled on ice. A standardized
quantity of 1μg RNA per sample was transcribed in cDNA
as described before [34]. A Mastercycler® ep realplex-S ther-
mocycler (Eppendorf AG, Hamburg, Germany) was used for
RT-qPCR as described before [34]. Each reaction mix com-
prised 7.5μl SYBR® Green JumpStart™ Taq ReadyMix™
(S4438; Sigma-Aldrich, Munich, Germany) as well as 1.5μl
of the respective cDNA solution (dilution 1 : 10) and
7.5 pmol (0.75μl) of the respective primer pair (3.75 pmol/-
primer). To achieve a total amount of 15μl, nuclease-free
H2O (T143, Carl Roth GmbH & Co. KG) was added accord-
ingly with all components (except cDNA) prepared as a
master mix to minimize manual pipetting-related technical
errors. cDNA ampliﬁcation was performed in 45 cycles
(95°C/5min initial heat activation, 95°C/10 s per cycle dena-
turation, 60°C/8 s annealing, and 72°C/8 s extension). At the
end of each extension step, SYBR Green I ﬂuorescence was
quantiﬁed at 521nm and Cq values were identiﬁed as second
derivative maximum of the ﬂuorescence signal curve
employing the software realplex (version 2.2, Eppendorf
AG, CalQPlex algorithm, Automatic Baseline, Drift Correc-
tion On). Normalization of target genes for assessment of rel-
ative gene expression was based on two reference genes
(RPL22/PPIB), which were validated before for hPDL ﬁbro-
blasts and the in vitromodel used [34]. We calculated relative
gene expression as 2−ΔCq [37] with ΔCq = Cq target gene –
Cq (mean RPL22/PPIB) according to MIQE guidelines [34].
RT-qPCR primer design and validation were performed
according to MIQE quality criteria as described before [34]
(Table 1, Supplementary Table 2).
2.4. Western Blot Quantiﬁcation of RANK-L Protein
Expression. Total protein was extracted from hPDL ﬁbro-
blasts on ice by applying 100μl CelLytic M (C2978; Sig-
ma-Aldrich) per well with additional proteinase inhibitors
(Carl Roth GmbH & Co. KG) and quantiﬁed by
Roti-Quant (K015.3; Carl Roth GmbH & Co. KG) as recom-
mended by the manufacturer. Equal protein amounts were
then separated by reducing SDS polyacrylamide gel electro-
phoresis (12%) and electro blotted onto a polyvinylidene
diﬂuoride (PVDF) membrane, blocked with 5% nonfat milk
in tris-buﬀered saline and 0.1% Tween 20, pH 7.5 (TBS-T) at
4°C overnight. For 1 h, anti-RANK-L (1 : 2000, ABIN500805,
antibodies-online, Aachen, Germany) or anti-HSP90
(1 : 500, Santa Cruz Biotech, Heidelberg, Germany) was
incubated in 0.5% milk in TBS-T. After 3x TBS-T washing
and blots were further incubated for 1 h at room tempera-
ture with horseradish peroxidase-conjugated anti-rabbit
IgG (1 : 5000, Pierce, Rockford, USA) in 0.5% milk in
TBS-T. Antibody binding was visualized by an enhanced
chemiluminescence system (Pierce, Rockford, USA), and
bands were quantiﬁed densitometrically with ImageJ (ver.
1.47, Wayne Rasband, National Institutes of Health, USA).
2.5. Enzyme-Linked Immunosorbent Assay (ELISA) of PG-E2,
sRANK-L, OPG, and ALPL. To quantify the concentration of
prostaglandin E2 (PG-E2), soluble receptor activator of
nuclear factor kappa b ligand (sRANK-L), osteoprotegerin
(OPG), and alkaline phosphatase (ALPL) in the cell culture
supernatant per well, which was related to the respective
number of hPDL ﬁbroblasts determined with a Beckman
Coulter counter (Z2 cell counter), ELISAs were performed
as recommended by the manufacturers’ instructions (PGE2:
514010, Cayman Chemical, Ann Arbor, USA; RANK-L:
RD193004200R, BioVendor, Brno, Czech Republic; OPG:
EHTNFRSF11B, Thermo Fisher Scientiﬁc; ALPL: OKEH00757,
Aviva Systems Biology, San Diego, USA).
2.6. hPDL-Mediated Osteoclastogenesis in Coculture Assessed
by TRAP Histochemistry. Stimulated hPDL ﬁbroblasts were
washed with PBS at the end of the 72 h incubation phase.
We then added a macrophage cell line (immortal
RAW264.7 cells, CLS Cell Lines Service, Eppelheim, Ger-
many) at a concentration of 70000 cells per well. By adding
the RAW cells after the phase of mechanical strain, we
avoided a possibly biasing force induction of RAW cell dif-
ferentiation [10]. We incubated the resulting coculture for
another 72 h under cell culture conditions [10, 16], enabling
osteoclastogenesis induced by hPDL ﬁbroblasts [38].
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Diﬀerentiated mononucleated and multinucleated TRAP-
positive cells were considered to be osteoclast precursor
and osteoclast-like cells, respectively [38, 39], as identiﬁed
by histochemical TRAP staining (tartrate-resistant acid
phosphatase, red) with TRAP-positive cells counted by a
blinded investigator at ×100 (Olympus IX50 microscope,
Olympus, Germany) in ten random ﬁelds of view per well
(biological replicate). The arithmetic mean was employed
for further analysis [10].
2.7. Cell Apoptosis and Necrosis as Assessed by Flow
Cytometry. FITC (ﬂuorescein isothiocyanate) annexin V
(apoptosis marker) and propidium iodide (PI, necrosis
marker) stainings were carried out according to the manu-
facturer’s instructions (FITC Annexin V Apoptosis Detec-
tion Kit I, 556547, BD Pharmingen, Heidelberg, Germany),
followed by FACS (ﬂuorescence-activated cell sorting, BD
FACSCalibur, Heidelberg, Germany). Membrane-adherent
hPDL ﬁbroblasts were washed twice with PBS (phosphate--
buﬀered saline) of 4°C and immediately resuspended at 106
cells/pro ml (Z2 cell counter, Beckman Coulter, Krefeld,
Germany) in 10x binding buﬀer (0.1M HEPES/NaOH
pH7.4, 1.4M NaCl, 25mM CaCl2). 100μl was then trans-
ferred to a 5ml FACS tube, and 5μl FITC annexin V and
5μl PI were added. hPDL ﬁbroblasts were gently vortexed
and incubated in the dark at room temperature for 15min.
Prior to ﬂow cytometry, 400μl binding buﬀer was added to
each tube (FSC: 5V, SSC: 349V, FITC: 350V, PerCP-Cy5-5:
and 450V; Threshold FSC: 5000; Laser Delay Blue: 0.00,
Red: 24.10; Area scaling Blue: 1.79, Red: 1.80; FSC Area
Scaling: 1.08).
2.8. Cell Cytotoxicity as Assessed by LDHAssay.Commercially
available lactate dehydrogenase (LDH) assays (04744926001,
Roche,Mannheim, Germany) were used according to theman-
ufacturer’s instructions. 100μl freshly prepared LDH solution
(22μl catalyst mixed with 1ml dye) was added to 100μl super-
natant and incubated in the dark at room temperature for
30min before adding 50μl of stop solution. An ELISA reader
(Multiskan GOMicroplate Spectrophotometer, Thermo Fisher
Scientiﬁc), was used to measure LDH activity (absorbance at
490nm), subtracting background absorbance at 690nm.
2.9. Cell Viability (Mitochondrial Enzymatic Activity) as
Assessed by MTT Assay. For MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazoliumbromid) assays, 400μl MTT
solution in PBS (5mg/ml, 4022.1, Carl Roth GmbH & Co.
KG) was added per well for the ﬁnal ﬁve hours of incubation.
Untreated hPDL ﬁbroblast controls 
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Figure 1: (a) In vitro model for the simulation of compressive orthodontic mechanical strain. hPDL: human periodontal ligament. (b)
Timeline of the in vitro experiments performed and ponding outcomes.
Table 1: RT-qPCR primer data for target genes as well as reference genes (PPIB, RPL22) used for normalization of gene expression. Primers
were not modiﬁed and synthesized and puriﬁed by Euroﬁns MWG Operon LLC (Huntsville, AL, USA; High Purity Salt Free Puriﬁcation
HPSF®).
Gene
symbol
Accession number
(NCBI GenBank)
Sequence
5′-forward primer-3′
Sequence
5′-reverse primer-3′
PPIB NM_000942.4 TTCCATCGTGTAATCAAGGACTTC GCTCACCGTAGATGCTCTTTC
RPL22 NM_000983.3 TGATTGCACCCACCCTGTAG GGTTCCCAGCTTTTCCGTTC
COX-2 NM_000963.3 GAGCAGGCAGATGAAATACCAGTC TGTCACCATAGAGTGCTTCCAAC
IL6 NM_000600.3 TGGCAGAAAACAACCTGAACC CCTCAAACTCCAAAAGACCAGTG
ALPL NM_000478.4 ACAAGCACTCCCACTTCATCTG GGTCCGTCACGTTGTTCCTG
VEGFA NM_001171623.1 TGCAGACCAAAGAAAGATAGAGC ACGCTCCAGGACTTATACCG
P4HA1 NM_000917.3 GCTCTCTGGCTATGAAAATCCTG GTGCAAAGTCAAAATGGGGTTC
COL1A2 NM_000089.3 AGAAACACGTCTGGCTAGGAG GCATGAAGGCAAGTTGGGTAG
FN1 NM_212482.1 GCCAGTCCTACAACCAGTATTCTC GCTTGTTCCTCTGGATTGGAAAG
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After, removal of the 1ml DMSO per well was added and
incubation continued at 37°C for another 5min measuring
ﬁnal absorbance (cell viability) at 550 nm with an ELISA
reader (Multiskan GO Microplate Spectrophotometer,
Thermo Fisher Scientiﬁc).
2.10. Statistical Analysis. Prior to statistical analysis, all abso-
lute data values were divided by the respective arithmetic
mean of the pressure-untreated 0μM etoricoxib controls to
obtain normalized data values relative to these controls, set
to 1. Using the software application SPSS® Statistics 24
(IBM®, Armonk, NY, USA), all data were tested for normal
distribution (Shapiro-Wilk test) and homogeneity of variance
(Levene’s test). Descriptive statistics are given as mean ±
standard deviation (M ± SD). The experimental groups were
compared by one-way ANOVAs with Tukey HSD post hoc
tests for pairwise comparisons. In case of variance heterogene-
ity, an adjustment byWelch’s test and Games-Howell post hoc
tests was used. All diﬀerences were considered statistically
signiﬁcant at p ≤ 0 05.
Suﬃcient statistical power was evaluated by an a-priori
power analysis with G∗Power (version 3.1.9.2) [40], based
on a clinically relevant 20% etoricoxib-induced reduction
of the mean- (±SD-) expected mechanical strain-elevated
PG-E2 concentration in the cell culture supernatant of
172.9 pg (±17.5 pg) per 100.000 cells (d = 1 976) [41] for
independent ANOVA post hoc t-test and Mann-Whitney
U tests, achieving an actual power of 86.9% and 84.9% at
α = 5% and β = 20% for the minimally used sample size of
n = 6 per experimental group.
3. Results
3.1. Eﬀects of Etoricoxib and Compressive Orthodontic
Mechanical Strain on the Expression and Secretion of
Proinﬂammatory Factors. Prostaglandin E2 (PG-E2) secre-
tion (ELISA, Figure 2(a)) was signiﬁcantly regulated both
by the mechanical strain applied to the hPDL cells and by
etoricoxib (F = 55 08; df1/2 = 5/13 56, p < 0 001). Force
application signiﬁcantly increased PG-E2 synthesis in the
control group (p = 0 024), whereas etoricoxib at cell medium
concentrations of 3.29μM and 5.49μM signiﬁcantly inhib-
ited PG-E2 synthesis in both the presence (p = 0 002) and
absence (p < 0 001) of mechanical compressive strain com-
pared to the respective 0μM controls.
Relative gene expression of cyclooxygenase 2 (COX-2)
(Figure 2(b), F = 22 366, df1/2 = 5/20 4, p < 0 001) and
interleukin 6 (IL-6, Figure 2(c), F = 13 399, df1/2 = 5/
21 024, p < 0 001) was signiﬁcantly induced by compressive
force application at all etoricoxib concentrations tested
(COX-2: p ≤ 0 009, IL-6: p ≤ 0 01), which did have no sig-
niﬁcant inﬂuence on the level of COX-2 (p ≥ 0 502) and
IL-6 (p ≥ 0 712) gene expression in neither the presence
or absence of compressive force.
3.2. Eﬀects of Etoricoxib and Compressive Orthodontic
Mechanical Strain on the RANK-L/OPG System and
hPDL-Mediated Osteoclastogenesis. Expression of the
osteoclastogenesis-stimulating factor RANK-L (receptor
activator of nuclear factor kappa b ligand) at the protein
level was signiﬁcantly induced by the mechanical strain
applied at all etoricoxib concentrations evaluated
(p ≤ 0 029), both in Western blot analysis (Figure 3(a),
F = 13 21, df = 5, p < 0 001) and in ELISA (Figure 3(b),
F = 27 614, df1/2 = 5/12 490, p < 0 001). Etoricoxib, on
the other hand, had no signiﬁcant impact on RANK-L pro-
duction in the presence (p ≥ 0 907) or absence (p ≥ 0 985) of
compressive force, as conﬁrmed by both analyses. Expression
of the RANK-L antagonist osteoprotegerin (OPG)
(Figure 3(c), F = 72 461, df1/2 = 5/13 503, p < 0 001) at
the protein level was signiﬁcantly suppressed by the com-
pressive force applied at all etoricoxib concentrations
(p ≤ 0 011), which had a signiﬁcant, but only minimal, inhib-
itory eﬀect in the absence of mechanical strain (p ≤ 0 028),
which was, however, not detectable during compression
(p ≥ 0 863). hPDL-mediated osteoclastogenesis in coculture
(Figure 3(d) and 3(e), F = 33 758, df1/2 = 5/21 573, p < 0 001),
as determined by TRAP staining, was signiﬁcantly induced
by the simulated orthodontic force application independent
of etoricoxib (p ≤ 0 002), which had no signiﬁcant inﬂuence
on osteoclastogenesis, at a concentration of neither 3.29μM
(p ≥ 0 947) nor 5.49μM (p ≥ 0 638).
3.3. Eﬀects of Etoricoxib and Compressive Orthodontic
Mechanical Strain on Bone Formation, Angiogenesis, and
Extracellular Matrix Remodeling. Relative gene expression
of alkaline phosphatase (ALPL) (Figure 4(a), F = 14 555,
df1/2 = 5/20 155, p < 0 001), which is known to be a bio-
chemical marker of bone formation and mineralization
[39], was signiﬁcantly elevated during the application of
compressive forces at all etoricoxib concentrations
(p ≤ 0 016), which was conﬁrmed at the protein level by
ELISA (p ≤ 0 046, Figure 4(b), F = 41 63, df1/2 = 5/13 826,
p < 0 001). 5.49μM etoricoxib at concurrent force applica-
tion induced a signiﬁcant increase in ALPL expression at
the translational level (p = 0 029), which was not detectable
at the mRNA level (p = 0 998), with no other signiﬁcant
etoricoxib eﬀects observed (p ≥ 0 568).
hPDL ﬁbroblast-mediated angiogenesis, as determined by
relative gene expression of vascular endothelial growth fac-
tor A (VEGF-A) (Figure 4(c), F = 24 976, df1/2 = 5/21 674,
p < 0 001), showed a signiﬁcant force-associated induction
independent of etoricoxib (p ≤ 0 004), which did have no
signiﬁcant eﬀects at neither of the two concentrations
applied 3.29μM (p ≥ 0 5) and 5.49μM (p ≥ 0 117).
Collagen synthesis and extracellular matrix remodeling,
represented by relative gene expression of prolyl 4-
hydroxylase subunit alpha-1 (P4HA1) (Figure 4(d), F =
35 732, df1/2 = 5/21 685, p < 0 001), alpha-2 subunit of
the ﬁbril-forming type I collagen (COL1A2) (Figure 4(e), F
= 14 354, df1/2 = 5/20 725, p < 0 001), and ﬁbronectin 1
(FN1) (Figure 4(f), F = 8 676, df1/2 = 5/21 859, p < 0 001),
were signiﬁcantly stimulated by compressive force application
at all etoricoxib concentrations tested, except for FN1
(p ≥ 0 236, P4HA1 p ≤ 0 023, and COL1A2 p ≤ 0 016). During
compression, 3.29μM etoricoxib signiﬁcantly elevated FN1
(p = 0 016) and 5.49μM etoricoxib FN1 (p = 0 005) and
COL1A2 (p = 0 042) gene expression, whereas P4HA1 gene
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expression was not signiﬁcantly inﬂuenced by etoricoxib at
the concentrations tested 3.29μM (p ≥ 0 464) and 5.49μM
(p ≥ 0 839).
3.4. Apoptosis, Necrosis, Cell Viability, and Etoricoxib
Cytotoxicity. As determined by FACS analysis (Figure 5(a)),
the percentage of apoptotic (Q4, F = 1 664, df= 5, p = 0 174)
and necrotic (Q2, F = 2 524, df= 5, p = 0 051) cells was not
signiﬁcantly increased by compressive force application or
etoricoxib independent of the concentration tested. As an
exception, 5.49μM etoricoxib and concurrent mechanical
strain evoked a signiﬁcant slight increase in the number of
necrotic cells (7.2%, p = 0 041) compared to 5.49μM without
pressure application (4.4%).
Cell viability, that is, mitochondrial enzymatic activ-
ity, as assessed by MTT assay (Figure 5(b), F = 904 714,
df1/2 = 5/20 707, p < 0 001), was signiﬁcantly reduced dur-
ing compression at all etoricoxib concentrations tested
(p < 0 001), whereas etoricoxib did not aﬀect cell viability
neither at 3.29μM (p ≥ 0 945) nor at 5.49μM (p ≥ 0 74).
No signiﬁcant cytotoxicity on hPDL ﬁbroblasts, as assessed
by LDH assay (Figure 5(c), F = 1 495, df=5, p = 0 209), was
detected for either pressure application (p ≥ 0 662) or
etoricoxib at 3.29μM (p ≥ 0 821) or 5.49μM (p ≥ 0 607).
4. Discussion
In our in vitro study on human periodontal ligament
(hPDL) ﬁbroblasts, we investigated possible eﬀects of etori-
coxib at cell medium concentrations corresponding to clini-
cally administered dosages and associated local tissue
concentrations in the presence and absence of physiological
mechanical compressive strain, occurring during orthodon-
tic tooth movement. We found a signiﬁcant inhibition of
prostaglandin E2 synthesis at both concentrations tested
according to the known pharmacodynamic mechanism of
etoricoxib, whereas expression of other inﬂammatory medi-
ators in hPDL ﬁbroblasts such as COX-2 and IL-6 as well as
RANK-L-/OPG-expression and hPDL-mediated osteoclas-
togenesis and angiogenesis (VEGF-A) was not signiﬁcantly
aﬀected. By contrast, etoricoxib, particularly at the high con-
centration, had a stimulating eﬀect on collagen synthesis and
remodeling of the extracellular matrix of the periodontal lig-
ament. Furthermore, increased anabolic activity regarding
bone formation is indicated by the observed elevated expres-
sion of alkaline phosphatase (ALPL), which is an important
biomarker for bone formation and generally reported to
have an increased biological activity in the periodontal lig-
ament compared to other connective tissues [42]. With the
exception of a slight signiﬁcant increase in necrotic cells
during force application at the high etoricoxib concentra-
tion tested, no adverse eﬀects on hPDL ﬁbroblasts regard-
ing apoptosis, necrosis, cell viability, or cytotoxicity were
detected, conﬁrming previous reports of its favorable side
eﬀect proﬁle [27].
For orthodontic tooth movement, mechanical forces are
applied to teeth, creating pressure and tension zones within
the periodontal ligament. Via the extracellular matrix and
most likely integrin (focal adhesions) as well as cAMP and
IP3 signaling [11], hPDL ﬁbroblasts put under mechanical
strain react by changing their expression pattern activating
various signaling pathways such as MAP kinase ERK, p38,
JNK, and NF-κB signaling [43, 44], leading to increased
synthesis of cyclooxygenase 2 (COX-2) [45] and thus
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Figure 2: Relative secretion of prostaglandin E2 (a) as well as expression of proinﬂammatory genes cyclooxygenase 2 (b) and interleukin 6 (c)
as normalized x-fold induction relative to 0 μM etoricoxib without mechanical strain. Asterisms without bars indicate signiﬁcant diﬀerences
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Figure 3: Relative expression of RANK-L/OPG and extent of hPDL ﬁbroblast-mediated osteoclastogenesis. (a) RANK-L expression
according to Western blot densitometry (N = 7), (b) sRANK-L and (c) OPG protein secretion according to ELISA (N = 2, n = 6), and (d,
e) osteoclastogenesis after coculture with RAW264.7 cells (TRAP staining and mono- and multinucleated osteoclast precursor and
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manuscript text. ∗p ≤ 0 05, ∗∗p ≤ 0 01, and ∗∗∗p ≤ 0 001. AU: arbitrary units. Bars show mean and standard deviation; TRAP:
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prostaglandins from arachidonic acid within 15 minutes
after force application [32], which was conﬁrmed by our
results. Hong et al. [46] could show that the mechanical
deformation of the cellular membrane itself leads to
increased prostaglandin synthesis, most likely due to an
exposure of phospholipids, enabling increased accessibility
for MAPK-phosphorylated and activated phospholipase A2
to synthesize arachidonic acid [6], thus further promoting
prostaglandin, prostacyclin, and thromboxane production
by cyclooxygenases 1 and 2 as well as leukotrienes by lipox-
ygenase 5 [47]. Prostaglandins [30, 31] as well as leukotri-
enes [48, 49] have been shown to be important autocrine
and paracrine mediators of mechanical (orthodontic) strain,
leading to increased synthesis of proinﬂammatory cytokines
such as IL-1, IL-6—as shown in our study—and chemokines
such as IL-8 [50–52], attracting lymphocytes from periph-
eral blood [53], which are the primary sources of RANK-L
in periodontitis [54]. This immigration of immune cells,
which further propagates inﬂammation and osteoclastogen-
esis, is promoted by an increased expression of vascular
endothelial growth factor (VEGF-A) by mechanically
stressed hPDL ﬁbroblasts, as evidenced by our results, fur-
thering angiogenesis and vasodilatation [55]. In addition,
prostaglandins and leukotrienes stimulate osteoclastogenesis
and bone resorption [31, 49] as well as induce the expression
of soluble and membrane-associated RANK-L, which has
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Figure 4: Relative expression of alkaline phosphatase (a, b) (bone formation), as well as of VEGF-A (c) (angiogenesis) and P4HA1, COL1A2,
and FN1 (d), (e), and (f), respectively (extracellular matrix remodeling), except for ELISA as normalized x-fold induction relative to 0 μM
etoricoxib without mechanical strain. Abbreviations: see manuscript text. ∗p ≤ 0 05, ∗∗p ≤ 0 01, and ∗∗∗p ≤ 0 001. AU: arbitrary units. Bars
show mean and standard deviation. ELISA: N = 2, n = 6; RT-qPCR: N = 3, n = 9; ELISA: enzyme-linked immunosorbent assay; RT-qPCR:
real-time reverse transcription quantitative polymerase chain reaction.
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been shown to be PG-E2 dependent [30], with expression of
its soluble decoy receptor osteoprotegerin (OPG) being
downregulated [56], conﬁrmed by our own data. The inter-
action of the RANK ligand with the RANK receptor as a
major stimulating factor for osteoclast diﬀerentiation and
activity [7] then enables bone resorption and orthodontic
movement of teeth through the alveolar bone, as evidenced
by the signiﬁcantly increased osteoclastogenesis observed
in hPDL RAW267.4-coculture [38]. On the other hand, sev-
eral studies have also shown that mechanical strain on hPDL
ﬁbroblasts also increases the expression of matrix metallo-
proteinases (MMP), their inhibitors (TIMP) [57], and colla-
gen synthesis [58], thus enabling increased remodeling of
the extracellular matrix [6, 11] promoting cell proliferation
as well as osteoblastogenesis and bone formation, which we
could corroborate in our study.
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Figure 5: Apoptosis and necrosis (FACS), cell viability (MTT), and cytotoxicity (LDH) of hPDL ﬁbroblasts incubated with rising etoricoxib
concentrations with and without mechanical strain. (a) Representative FACS distributions (M ± SD, positive cells relative to total cells (%)) of
apoptotic (Q4, FITC annexin V), necrotic (Q2, propidium iodide), and viable cells (Q3). N = 3, n = 6. (b) Cell viability as assessed by MTT
assay; N = 3, n = 9. (c) Cytotoxicity assessed by LDH assay; N = 3, n = 9. All values given as normalized x-fold induction relative to 0μM
etoricoxib without mechanical strain. ∗p ≤ 0 05, ∗∗p ≤ 0 01, and ∗∗∗p ≤ 0 001. AU: arbitrary units. Bars show mean and standard deviation.
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The observed signiﬁcant inhibition of prostaglandin E2
synthesis by etoricoxib at both concentrations evaluated is
in accordance with its known pharmacodynamic mecha-
nism, which selectively inhibits inﬂammation-induced
cyclooxygenase 2 (COX-2) with a preference of 344 : 1 com-
pared to the constitutively expressed COX isoform 1 [24,
25, 27, 35]. Both cyclooxygenases catalyze the synthesis of
prostaglandins from arachidonic acid [47]. Despite prosta-
glandins being potent stimulators of proinﬂammatory cyto-
kine expression [50–52] as well as osteoclastogenesis [31],
their signiﬁcant inhibition by both etoricoxib concentra-
tions tested did not signiﬁcantly aﬀect COX-2 and IL-6
gene expression nor the RANKL-OPG ratio or osteoclasto-
genesis in coculture of hPDL ﬁbroblasts with RAW264.7
cells. A possible explanation for this phenomenon could
be the extremely high COX-2 selectivity of etoricoxib,
which basically only targets COX-2 leaving COX-1 activity
unaﬀected, as well as the presence of other arachidonic
acid-metabolizing enzymes such as lipoxygenase 5 as well
as proinﬂammatory cytokines. The increasingly available
arachidonic acid from membrane lipid exposure [46] and
MAPK-initiated phospholipase A2 expression [6] during
mechanical strain could thus be metabolized to other pros-
taglandins than PG-E2 by COX-1 as well as by lipoxygenase
5 to leukotrienes, which have been shown to be potent
stimulators of osteoclastogenesis as well [49], compensating
for the loss of COX-2 activity and prostaglandin E2
synthesis. Furthermore, the observed etoricoxib-unaﬀected
force-elevated expression of IL-6 or other cytokines and
chemokines such as IL-8 might compensate for the loss of
prostaglandin activity, since IL-6 and IL-11 have been
shown to directly stimulate osteoclast activity by a
RANKL-independentmechanism [59] and elevated chemokine
expression might attract RANKL-producing T-lymphocytes
into the periodontal ligament [53, 54].
COX-2 selectivity of NSAID and its eﬀects on osteoclas-
togenesis and orthodontic tooth movement is still controver-
sial in the current literature [15, 19, 20, 23]. This is most
likely due to various clinically more or less relevant dosages
investigated with pharmacodynamic eﬀects being dose
dependent as well as substantially diﬀering COX-2 selectivity
of the various coxibs available with celecoxib and parecoxib
being only 30 or 60 times more selective, respectively. A pre-
vious study on the partially COX-2-selective (11 : 1) NSAID
meloxicam [10] showed a less pronounced inhibitory eﬀect
on hPDL ﬁbroblast-mediated osteoclastogenesis than con-
ventional nonselective NSAID, but a more profound eﬀect
than most coxibs tested up to the highly selective etoricoxib
of this study having no eﬀects. Based on the available evi-
dence and the results of the present study, it thus seems likely
that increasing COX-2 selectivity is associated with less
eﬀects on hPDL ﬁbroblast-mediated osteoclastogenesis and
thus orthodontic tooth movement. Further studies directly
comparing NSAID of various selectivity in comparable, clin-
ically relevant dosages and concentrations should therefore
be performed to clarify and corroborate this hypothesis.
No previous reports on the eﬀects of etoricoxib on hPDL
or other ﬁbroblasts have been found in the literature. Avail-
able animal studies in a rat model of periodontitis, however,
have reported suppressive eﬀects of etoricoxib on inﬂamma-
tion, osteoclastogenesis, and alveolar bone loss [60, 61],
which could, however, not be replicated in man [62], corre-
sponding to our own results on human PDL ﬁbroblasts. In
contrary to the less COX-2-selective celecoxib [63], etori-
coxib had no negative impact on alveolar bone healing in
rats [64], whereas a reported antiangiogenetic eﬀect in
experimental lung cancer [65] was not observed at the etor-
icoxib concentrations used in our study.
Available literature on the eﬀects of other coxibs on
hPDL or other ﬁbroblasts is scarce with only a few reports
available. Römer et al. showed a distinct inhibitory eﬀect of
the distinctly less COX-2-selective celecoxib on the expres-
sion of inﬂammatory cytokines and RANK-L by hPDL
ﬁbroblasts stimulated with pressure and bacterial toxins
[41]. Also, in synovial ﬁbroblasts from the temporoman-
dibular joint of patients with rheumatoid arthritis, cele-
coxib reduced COX-2 and IL-6 expression by suppression
of PG-E2 synthesis during stimulation of cells with
PG-E2/IL-1β [66]. In contrary to our own observations,
an inhibition of cell proliferation and collagen synthesis
of celecoxib-stimulated NIH/3T3 ﬁbroblasts via ERK1/2
and SMAD2/3 phosphorylation was reported [67] as well
as a proapoptotic eﬀect on synovial ﬁbroblasts [68]. Further
investigations have however corroborated that the reported
antiproliferative and proapoptotic eﬀects of celecoxib are
not class eﬀects of coxibs [68, 69], which might explain
the diﬀering results to etoricoxib tested in this study limit-
ing comparability.
For our study, we used an established and valid in vitro
model for the simulation of physiological orthodontic
compressive forces. 2 g/cm2 have been shown to elicit the
maximum cellular response of hPDL ﬁbroblasts under
compressive strain with 4 g/cm2 causing cellular damage
[30]. To support suﬃcient nutrition of cells beneath the
sterilized glass plate, which is ensured by diﬀusion from
the lateral sides, we placed it into full medium for 15min
prior to the start of experiments to ensure surface satura-
tion with proteins [41].
In coculture experiments on hPDL-mediated osteoclas-
togenesis, an established coculture model (RAW264.7 mac-
rophages) was used [70–72]; however, both mononucleated
and multinucleated TRAP-positive cells, corresponding to
osteoclast precursor and osteoclast-like cells [39], were con-
sidered for analysis, which needs to be taken into account
when comparing our results to those of other studies.
We primarily used LDH assays to assess cytotoxicity
based on the cell membrane damage evaluated in this test,
whereas MTT assays were used to assess cell viability, that
is, metabolic activity, which does not necessarily correspond
to cell death but reduced cell function and metabolism. Since
LDH assays did not show a signiﬁcant inﬂuence of either
compressive force or etoricoxib regarding cytotoxicity, this
observation concurs well with our FACS results. MTT assays
also did not yield any signiﬁcant eﬀect of etoricoxib on cell
viability, whereas the compressive force applied signiﬁcantly
reduced cell viability, that is, mitochondrial enzymatic activ-
ity, as assessed by the MTT assay. We thus hypothesize that
either the mechanical stress itself [73] or an accompanying
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lack of oxygen [74] in our in vitro model, which is also
supposed to occur during orthodontic tooth movement
in vivo [75], most likely attenuated PDL ﬁbroblast cell
metabolism to a signiﬁcant degree, whereas cell death was
not signiﬁcantly induced.
Although a direct clinical extrapolation of biological sig-
niﬁcance to the clinical situation is not possible, we
attempted to maximize generalizability and translatability
of our results by choosing etoricoxib concentrations, which
are likely to occur in the clinical context locally within the
periodontal ligament microenvironment during medication.
These were supposed to correspond to steady-state blood
plasma concentrations of normal (90mg/day) and subtoxic
(150mg/day) etoricoxib dosing reached in man [36], since
the extracellular ﬂuid within the periodontal ligament is a
plasma transudate from the periodontal capillaries [76].
Thus, the assumption made that local etoricoxib concentra-
tions in the PDL microenvironment correspond to etori-
coxib concentrations reached in blood plasma should be
valid. Approximated mean steady-state plasma concentra-
tions of etoricoxib, which shows linear pharmacokinetics in
man in dosages from 30-240mg/day [35], were calculated
from known 24h AUC values for multiple dosing of
120mg/day (37.83μg·h/ml) by dividing the extrapolated
AUC24h for normal 90mg/day (28.37μg·h/ml) and subtoxic
150mg/day (47.29μg·h/ml) dosing by 24 h [35], resulting in
mean blood plasma concentrations of 1.18μg/ml (3.29μM,
molar mass etoricoxib = 358 84 g/mol) and 1.97μg/ml
(5.49μM), respectively, which were used as experimental
etoricoxib concentrations in the present study.
5. Conclusions
Based on our results, it seems likely that etoricoxib medica-
tion, that is a highly selective inhibition of COX-2, at cell
medium concentrations corresponding to clinically adminis-
tered dosages and associated local tissue concentrations
within the periodontal ligament does not have substantial
eﬀects on hPDL ﬁbroblast-mediated periodontal inﬂamma-
tion, extracellular matrix remodeling, RANK-L/OPG expres-
sion, and osteoclastogenesis during simulated orthodontic
compressive force application. Due to its also favorable side
eﬀect proﬁle and high analgesic eﬃcacy, particularly for
orthodontic pain, it could therefore be a valid analgesic
during orthodontic treatment.
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